These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 27770553)

  • 1. Antiviral treatment and liver-related complications in hepatitis delta.
    Wranke A; Serrano BC; Heidrich B; Kirschner J; Bremer B; Lehmann P; Hardtke S; Deterding K; Port K; Westphal M; Manns MP; Cornberg M; Wedemeyer H
    Hepatology; 2017 Feb; 65(2):414-425. PubMed ID: 27770553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients.
    Scheller L; Hilgard G; Anastasiou O; Dittmer U; Kahraman A; Wedemeyer H; Deterding K
    Medicine (Baltimore); 2021 Jul; 100(28):e26571. PubMed ID: 34260535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis D: A Review.
    Negro F; Lok AS
    JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN).
    Wranke A; Pinheiro Borzacov LM; Parana R; Lobato C; Hamid S; Ceausu E; Dalekos GN; Rizzetto M; Turcanu A; Niro GA; Lubna F; Abbas M; Ingiliz P; Buti M; Ferenci P; Vanwolleghem T; Hayden T; Dashdorj N; Motoc A; Cornberg M; Abbas Z; Yurdaydin C; Manns MP; Wedemeyer H; Hardtke S;
    Liver Int; 2018 May; 38(5):842-850. PubMed ID: 28963781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
    Sheng WH; Hung CC; Kao JH; Chang SY; Chen MY; Hsieh SM; Chen PJ; Chang SC
    Clin Infect Dis; 2007 Apr; 44(7):988-95. PubMed ID: 17342655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Delta Hepatitis: Today and in the Future - A review.
    Bahcecioglu IH; Sahin A
    Infect Dis (Lond); 2017 Apr; 49(4):241-250. PubMed ID: 28092214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological responses of peginterferon alpha add-on therapy in patients with chronic hepatitis B with advanced liver fibrosis after long-term nucleos(t)ide analog treatment.
    Li G; Zhang Q; Yu Y; Qiu C; Zhang H; Zhang M; Song Z; Yang Y; Hong J; Lu J; Li N; Tang Q; Xu L; Wang X; Zhang W; Chen Z
    J Viral Hepat; 2019 Jul; 26 Suppl 1():50-58. PubMed ID: 31380590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.
    Romeo R; Del Ninno E; Rumi M; Russo A; Sangiovanni A; de Franchis R; Ronchi G; Colombo M
    Gastroenterology; 2009 May; 136(5):1629-38. PubMed ID: 19208358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort.
    Bockmann JH; Grube M; Hamed V; von Felden J; Landahl J; Wehmeyer M; Giersch K; Hall MT; Murray JM; Dandri M; Lüth S; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
    BMC Gastroenterol; 2020 Jan; 20(1):24. PubMed ID: 32000689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis delta and HIV infection.
    Calle Serrano B; Manns MP; Wedemeyer H
    Semin Liver Dis; 2012 May; 32(2):120-9. PubMed ID: 22760651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
    Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çalişkan A; Karatayli E; Karatayli S; Bozdayi AM; Koh C; Heller T; Idilman R; Glenn JS
    Hepatology; 2018 Apr; 67(4):1224-1236. PubMed ID: 29152762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
    Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
    Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic hepatitis B and D (delta) : Current and future treatments].
    Wortmann N; Höner Zu Siederdissen C; Cornberg M
    Internist (Berl); 2018 Jun; 59(6):519-527. PubMed ID: 29761292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta.
    Wranke A; Hardtke S; Heidrich B; Dalekos G; Yalçin K; Tabak F; Gürel S; Çakaloğlu Y; Akarca US; Lammert F; Häussinger D; Müller T; Wöbse M; Manns MP; Idilman R; Cornberg M; Wedemeyer H; Yurdaydin C
    J Viral Hepat; 2020 Dec; 27(12):1359-1368. PubMed ID: 32707605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
    Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
    Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of compensated viral B and D cirrhosis.
    Gheorghe L; Iacob S; Simionov I; Vadan R; Gheorghe C; Iacob R; Parvulescu I; Constantinescu I
    Rom J Gastroenterol; 2005 Dec; 14(4):329-35. PubMed ID: 16400347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.